News | March 16, 2012

Depression Increases Death Risk in Coronary Stent Patients

March 16, 2012 - Depression increases the risk of death in patients who have a coronary stent implanted. After seven years of follow up, depressed patients were 1.5 times more likely to have died than non-depressed patients. The findings were independent of age, gender, clinical characteristics, anxiety and the distressed (Type D) personality.

The research was presented at the 12th Annual Spring Meeting on Cardiovascular Nursing, March 16-17, in Copenhagen, Denmark.

Depression has been associated with poor outcomes in coronary artery disease but previous studies have mainly looked at short-term effects, primarily in patients who have had a myocardial infarction or a coronary bypass operation. The current study (FPN 17) investigated the impact of depression on mortality during a seven-year follow up period in patients treated with percutaneous coronary intervention (PCI).

For the study, 1,234 PCI patients aged 26-90 years (average age 62) from the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry completed the Hospital Anxiety and Depression Scale (HADS) to assess depression six months after having a stent implanted. The endpoint was all-cause mortality.

The prevalence of depression was 26.3 percent (324 out of 1234 patients). After seven years there were 187 deaths in total (15.2 percent). The incidence of all-cause mortality in depressed patients was 23.5 percent (76 out of 324 patients) versus 12.2 percent (111 out of 910 patients) in non-depressed patients.

Depression was independently associated with all-cause mortality (hazard ratio=1.56; 95 percent confidence interval [1.03–2.35], p = .035) after adjusting for sociodemographics (age, gender), clinical characteristics, anxiety and the Type D personality. Clinical characteristics included type of stent (drug eluting/bare metal), number of vessels obstructed, body mass index, past cardiac surgery or myocardial infarction, indication for the PCI procedure, coronary risk factors (hypertension, hypercholesterolemia, diabetes, family history of cardiovascular disease, smoking) and cardiac medications (aspirin, ACE inhibitors, beta blockers, calcium antagonists, diuretics, nitrates and statins).

Male gender, older age, and diabetes mellitus were also significantly associated with an increased risk of death after seven years of follow up, whereas statins were associated with a reduced risk. Anxiety and Type D personality had no significant effect on all-cause mortality.

“The main finding is that patients who are depressed after coronary stenting have a worse prognosis,” says lead author Nikki Damen, a Ph.D. student at Tilburg University in the Netherlands. “They die earlier than non-depressed patients.”

The reasons for the finding are under investigation. One possible explanation is that depressed patients may have less healthy lifestyles with regard to smoking, drinking alcohol, physical activity and diet, and may be less likely to take their medications. Another possible explanation is that depression could alter the activity of the sympathetic nervous system, leading to increases in heart rate and blood pressure.

“Doctors and nurses have traditionally focused on medical factors like diabetes or family history of cardiovascular disease when assessing PCI patients’ risk of death, but that’s not the whole picture,” says Damen. “Psychological factors do matter as well, in combination with the medical factors.”

She adds: “More research is needed to determine how to screen for depression in cardiovascular patients, and then how to provide treatment.”

For more information: www.escardio.org

Related Content

First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
BioCardia Announces 12-Month Results from TRIDENT Trial of Stem Cell Delivery System
News | Stem Cell Therapies| September 26, 2017
BioCardia Inc. recently announced 12-month results from the Phase II TRIDENT clinical trial, conducted by the...
News | Vena Cava Filters| September 26, 2017
September 26, 2017 — The one-year results of the SENTRY...
Treatment of Heart Attack Patients Depends on Cancer History
News | Cardio-oncology| September 26, 2017
Treatment of heart attack patients depends on their history of cancer, according to research published recently in...
CardiAMP Heart Failure Trial Design Presented at Texas Heart Institute Symposium
News | Heart Failure| September 25, 2017
BioCardia Inc. announced the trial design for its pivotal Phase III CardiAMP Heart Failure Trial was presented during...
Overlay Init